Cancer vaccine partnering agreements
Upcoming SlideShare
Loading in...5
×
 

Cancer vaccine partnering agreements

on

  • 117 views

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Statistics

Views

Total Views
117
Views on SlideShare
117
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Cancer vaccine partnering agreements Cancer vaccine partnering agreements Document Transcript

    • Cancer Vaccine Partnering Agreements The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancervaccine partnering deals and agreements entered into by the worlds leading healthcare companies. Trends incancer vaccine partnering deals Disclosed headlines, upfronts, milestones and royalties by stage ofdevelopment Cancer vaccine partnering contract documents Top cancer vaccine deals by value The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancervaccine partnering deals and agreements entered into by the worlds leading healthcare companies. The reportprovides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. Themajority of deals are discovery or development stage whereby the licensee obtains a right or an option right tolicense the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborativeR&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insightinto the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilstmany smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms ofhow payments are triggered – contract documents provide this insight where press releases do not. This report contains over 500 links to online copies of actual cancer vaccine deals and where available,contract documents as submitted to the Securities Exchange Commission by companies and their partners.Contract documents provide the answers to numerous questions about a prospective partner’sflexibility on a wide range of important issues, many of which will have a significant impact on eachparty’s ability to derive value from the deal. The initial chapters of this report provide an orientation of cancer vaccine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst Chapter 2 provides an overview of the trends in cancer vaccine dealmaking since 2007, including details ofdisclosed headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading cancer vaccine deals since 2007. Deals are listed by headlinevalue. Where the deal has an agreement contract published at the SEC a link provides online access to thecontract. Chapter 4 provides a comprehensive and detailed review of cancer vaccine partnering deals signed andannounced since 2007, and where available, a contract document is available in the public domain. Thechapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D,co-promotion, licensing etc), and specific oncology therapy focus. Each deal title links via Weblink to anonline version of the deal record and where available, the contract document, providing easy access to eachcontract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in cancer vaccinepartnering and dealmaking since 2007. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in theCancer Vaccine Partnering Agreements
    • research, development and commercialization of cancer vaccine technologies and products. Report scope Cancer Vaccine Partnering Agreements is intended to provide the reader with an in-depth understanding andaccess to cancer vaccine trends and structure of deals entered into by leading companies worldwide. Cancer Vaccine Partnering Agreements includes: Trends in cancer vaccine dealmaking in the biopharma industry since 2007 Analysis of cancer vaccine dealstructure Access to headline, upfront, milestone and royalty data Access to over 500 cancer vaccine dealrecords The leading cancer vaccine deals by value since 2007 Includes adjuvant and drug delivery deals andalliances since 2007 In Cancer Vaccine Partnering Agreements, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific oncologytherapy target Each deal title links via Weblink to an online version of the deal record and where available, the contractdocument, providing easy access to each contract document on demand. The Cancer Vaccine Partnering Agreements report provides comprehensive access to available deals andcontract documents for over 500 cancer vaccine deals. Analyzing actual contract agreements allowsassessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partnercompany? What exclusivity is granted? What is the payment structure for the deal? How aresales andpayments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRshandled and owned? Who is responsible for commercialization? Who is responsible for development, supply,and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Underwhat conditions can the deal be terminated? What happens when there is a change of ownership? Whatsublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the companyinsist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?Which jurisdiction does the company insist upon for agreement law? Benefits: In-depth understanding of cancer vaccine deal trends since 2007 Access to headline, upfront, milestone androyalty data Acces to the structure of cancer vaccine agreements with numerous real life case studiesComprehensive access to over 500 actual cancer vaccine deals entered into by the world’s biopharmacompanies Insight into the terms included in a cancer vaccine agreement, together with real world clauseexamples Understand the key deal terms companies have agreed in previous deals Undertake duediligencetable Of Contentsexecutive Summarychapter 1 – Introductionchapter 2 – Trends In Cancer Vaccine DealmakingCancer Vaccine Partnering Agreements
    • 2.1. Introduction2.2. Cancer Vaccine Partnering Over The Years2.3. Bigpharma Cancer Vaccine Dealmaking Activity2.4. Bigpharma Not Active In Cancer Vaccine Partnering2.5. Cancer Vaccine Partnering By Deal Type2.6. Cancer Vaccine Partnering By Stage Of Development2.7. Cancer Vaccine Partnering By Cancer Indication2.8. Disclosed Deal Terms For Cancer Vaccine Partnering2.8.1 Cancer Vaccine Partnering Headline Values2.7.2 Cancer Vaccine Deal Upfront Payments2.7.3 Cancer Vaccine Deal Milestone Payments2.7.4 Cancer Vaccine Royalty Rateschapter 3 – Leading Cancer Vaccine Deals3.1. Introduction3.2. Top Cancer Vaccine Deals By Valuechapter 4 – Cancer Vaccine Dealmaking Directory4.1. Introduction4.2. Company A-z4.3. By Stage Of Developmentdiscoverymarketedphase Iphase Iiphase Iiipre-clinicalregistration4.4. By Deal Typeasset Purchasebigpharma Outlicensingco-developmentcollaborative R&dco-marketcontract Serviceco-promotioncradacross-licensingdevelopmentdistributionequity PurchaseCancer Vaccine Partnering Agreements
    • evaluationgrantjoint Venturelicensingmanufacturingmarketingmaterial Transferoptionresearchsettlementsub-licensesupplytechnology Transferterminationwarranty4.5. By Oncology Therapy Areabladder Cancerbrain Cancerbreast Cancercervical Cancercolorectal Cancerhead And Neck Cancerkidney Cancerleukemiaacute Lymphoblastic Leukemiaacute Myelogenous Leukemiachronic Lymphocytic Leukemialiver Cancerlung Cancerlymphomanon Hodgkins Lymphomamelanomabone Metastasesovarian Cancerpancreatic Cancerprostate Cancerrenal Cell Carcinomasolid Tumors4.6. By Related Technologyadjuvantsdrug DeliveryinjectableCancer Vaccine Partnering Agreements
    • chapter 5 –partnering Resource Center5.1. Online Partnering5.2. Partnering Events5.3. Further Reading On Dealmakingappendicesappendix 1 – Deal Type Definitionsappendix 2 – Example Cancer Vaccine Partnering Agreementabout Wildwood Venturescurrent Partneringcurrent Agreementsrecent Report Titles From Currentpartneringorder Form – Therapy Reportsorder Form – ReportsAbout Us:Transparency Market Research is a market intelligence company providing global business informationreports and services. Our exclusive blend of quantitative forecasting and trends analysis providesforward-looking insight for thousands of decision makers. We are privileged with highly experienced team ofAnalysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques togather, and analyze information. Our business offerings represent the latest and the most reliable informationindispensable for businesses to sustain a competitive edge.Contact:ResearchMoz90 State Street,Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usBlog: http://researchmoz.blogspot.com/Website: http://www.researchmoz.us/Cancer Vaccine Partnering Agreements